- Home
- NEN vs CLLS Comparison
NEN vs CLLS Comparison
Compare NEN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- CLLS
- Stock Information
- Founded
- NEN 1977
- CLLS 1999
- Country
- NEN United States
- CLLS France
- Employees
- NEN N/A
- CLLS N/A
- Industry
- NEN Building operators
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- CLLS Health Care
- Exchange
- NEN Nasdaq
- CLLS Nasdaq
- Market Cap
- NEN 282.1M
- CLLS 240.2M
- IPO Year
- NEN N/A
- CLLS 2007
- Fundamental
- Price
- NEN $80.19
- CLLS $1.57
- Analyst Decision
- NEN
- CLLS Buy
- Analyst Count
- NEN 0
- CLLS 3
- Target Price
- NEN N/A
- CLLS $7.00
- AVG Volume (30 Days)
- NEN 121.0
- CLLS 56.7K
- Earning Date
- NEN 01-01-0001
- CLLS 11-04-2024
- Dividend Yield
- NEN 1.99%
- CLLS N/A
- EPS Growth
- NEN 67.91
- CLLS N/A
- EPS
- NEN 3.91
- CLLS N/A
- Revenue
- NEN $81,169,352.00
- CLLS $36,042,000.00
- Revenue This Year
- NEN N/A
- CLLS $271.02
- Revenue Next Year
- NEN N/A
- CLLS $33.48
- P/E Ratio
- NEN $20.63
- CLLS N/A
- Revenue Growth
- NEN 10.81
- CLLS 46.96
- 52 Week Low
- NEN $67.04
- CLLS $1.53
- 52 Week High
- NEN $84.00
- CLLS $3.55
- Technical
- Relative Strength Index (RSI)
- NEN 38.67
- CLLS 27.91
- Support Level
- NEN $82.10
- CLLS $1.85
- Resistance Level
- NEN $82.74
- CLLS $2.09
- Average True Range (ATR)
- NEN 0.08
- CLLS 0.09
- MACD
- NEN -0.29
- CLLS -0.04
- Stochastic Oscillator
- NEN 0.00
- CLLS 0.00
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.